Navigation Links
Accentia announces investigational new drug application for Revimmune for refractory MS
Date:10/9/2007

TAMPA, FL(October 9, 2007)Accentia Biopharmaceuticals announces that it met with the Food and Drug Administration (FDA) on September 26, 2007 for a scheduled pre-Investigational New Drug (pre-IND) meeting on Revimmune. The FDA has indicated its support for Accentia to submit an IND for a pivotal Phase 3 randomized controlled, multi-center clinical trial of Revimmune, the companys potential therapeutic for refractory, relapsing-remitting Multiple Sclerosis (MS). The FDA indicated that they support the proposed submission from Accentia and that they are in overall agreement with the proposed design of the Accentia clinical program.

The Revimmune MS study will enroll subjects in a one-year study comparing baseline disability to disability at month 12 with an interim data analysis. After consultation with the FDA on the design of the trial, it was agreed that the primary endpoint will be recovery of lost function and that this unique study will be done under a special protocol assessment (SPA). Accentia will proceed diligently with submission of the IND under a SPA and of an application for Fast Track status, and currently projects commencement of the Phase 3 study in the first half of 2008. A Special Protocol Assessment is a declaration from the Food and Drug Administration that a proposed Phase 3 trial 's design, clinical endpoints, and statistical analyses are acceptable for FDA approval. All prior approved therapeutics suppress rather than eliminate autoimmunity and they have used the more limited indication of a reduction in the rate of progression of disability as their primary endpoint, not a reduction in disability as for Revimmune.

Revimmune is the first drug to propose restoration of lost function in MS patients. Using a patent-pending, ultra-high intensity, short-course of an intravenous formulation of cyclophosphamide, Revimmune is intended to reboot a patients immune system, thereby eliminating autoimmunity, whereas current ther
'/>"/>

Contact: Adam Holdsworth
aholdsworth@investorrelationsgroup.com
212-825-3210
The Investor Relations Group
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. New lease of life for asthmatics by Accentia Biopharmaceuticals
2. PM announces a new health care order for India
3. Ramdoss Announces Introduction of RCH-II
4. Britain Announces Third Transfusion Related Mad Cow Case
5. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
6. Tibet Announces the Dalai Lama’s Tour of South Americ
7. NHS announces further Cost cutting Measures
8. Indian PM Announces Of Setting Up India Study Center At Tashkent
9. PowderMed Announces Needle-Less Flu Vaccine
10. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
11. Australian Government Announces Survey To Tackle Childhood Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... New York (PRWEB) March 02, 2015 ... Recovery at Recovery Unplugged™—will be delivering a plenary ... Singer/Songwriter's Perspective on the Art of Healing and ... Disorders (NCAD) and Behavioral Healthcare Executive Summit (BHES).     ... name, Mr. Supa’s songs have been recorded by ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 The ... grow at a CAGR of 6.1% to reach ... 2014. , Factors such as advantages of ... healthcare costs owing to minimally invasive surgeries and ... population are driving the global minimally invasive surgical ...
(Date:3/2/2015)... DC (PRWEB) March 02, 2015 Atlantic ... publication of AIS’s Directory of Health Plans: 2015 ... resource available on the U.S. health plan market, with ... in the United States. , Available as a ... Summary” of enrollment trends in quick-view tables and charts, ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 In light ... of anticoagulant Xarelto (rivaroxaban) tablets, Ford & ... may be helpful for future users, but may come ... injuries from taking the drug. The FDA has now ... under Adverse Reactions on Xarelto's label. The term “cytolytic ...
(Date:3/2/2015)... ProvidaStaff has announced today that it is changing ... EDU Healthcare to reflect better on the commitment ... nationwide. , “ProvidaStaff has always been a leading healthcare ... Angela M. Lewis, President of ProvidaStaff. “We continue to ... of EDU Healthcare better aligns our services to our ...
Breaking Medicine News(10 mins):Health News:Richie Supa Announced as a Plenary Speaker at NCAD 2015 2Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:Now Available from AIS: 12th Edition of Annual Book Containing Health Plan Enrollment Data, Contact Information 2Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 2Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 3Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 4Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 2Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 3
... finds , WEDNESDAY, Feb. 17 (HealthDay News) -- Good ... improve their odds of staying healthy: baked rhubarb may ... garden rhubarb for 20 minutes dramatically boosted levels of ... polyphenols selectively kill or prevent the growth of cancer ...
... Rural areas tend to fare worse than urban locales, ... -- Want to know how healthy your county is? ... ranking of nearly every county in the nation shows ... on where they live. , Researchers from University of ...
... , GREENBRAE, Calif. , Feb. 17 ... of transformational media, announced today the release of Sound Sanctuaries ... Malkin . , Designed to help listeners experience deep inner peace ... moving music by Malkin that he says will "awaken the spirit ...
... N.C. , Feb. 17 MedCath Corporation (Nasdaq: ... they have entered into a definitive agreement to sell substantially ... David,s Healthcare Partnership, L.P. ("St. David,s"). The transaction is expected ... to customary closing conditions and regulatory requirements. , The sale ...
... , ... Services marked the start of 2010 with the official launch of a new state-of-the-art ... industries, this latest addition to the Almac services portfolio is set to revolutionise the ... ...
... MyNursingUniforms ... nursing uniform store. , ... February 17, 2010 -- MyNursingUniforms (MNU), a leader in online retail for nursing uniforms and ... , ,MNU made the expansion to their online store in both the shoe and medical ...
Cached Medicine News:Health News:County-By-County Report Sizes Up Americans' Health 2Health News:County-By-County Report Sizes Up Americans' Health 3Health News:New CD Collections Promise to Create a Sound Sanctuary in Your Home, Office, or Car 2Health News:MedCath Enters Definitive Agreement To Sell Heart Hospital of Austin 2Health News:Almac Launches New STEMS System to Transform Temperature Controlled Shipment Monitoring in Clinical Trials 2Health News:Almac Launches New STEMS System to Transform Temperature Controlled Shipment Monitoring in Clinical Trials 3Health News:MyNursingUniforms Adds Skechers Brand Name Shoes and Scrubs to Store 2
(Date:3/2/2015)... , March 2, 2015  Delcath Systems, Inc. ... medical device company focused on oncology with an emphasis ... announces that Company management will participate in the upcoming ... March 8-11, 2015 at the Ritz Carlton Laguna Niguel ... Jennifer Simpson , PhD, MSN, CRNP, Delcath,s interim President ...
(Date:3/2/2015)... NORTH HOLLYWOOD, Calif. , March 2, 2015 ... improving the quality of life of myeloma patients ... once again declared the month of March to ... IMF first established March as Myeloma Awareness Month ... information about the disease through local community events, ...
(Date:3/2/2015)... DUBLIN , Mar. 02, 2015 Research ... announced the addition of the "Lopinavir - ... , Imagine having your own ... of a button. Used by the ... over 10 years, these searches are the benchmark ...
Breaking Medicine Technology:Delcath To Present At The 27th Annual Roth Conference 2Delcath To Present At The 27th Annual Roth Conference 3International Myeloma Foundation Declares March "Myeloma Awareness Month" 2International Myeloma Foundation Declares March "Myeloma Awareness Month" 3Global Comprehensive Lopinavir Patent Search Online Portal 2015 2
... 4, 2011 WebMD Health Corp. (Nasdaq: WBMD ... deliver a presentation at the UBS 21st Annual Global Healthcare ... ET. Investors, analysts and the general public are ... presentation over the Internet.  The broadcast can be accessed at ...
... K-V Pharmaceutical Company (NYSE: KVa/KVb) (the "Company"), a ... informed by Hologic, Inc. that the U.S. Food and ... injection).  Makena, commonly referred to as "17P," is the ... risk of preterm birth in women with a singleton ...
Cached Medicine Technology:FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 2FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 3FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 4FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 5FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 6FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 7FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 8FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 9FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 10FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 11FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 12
... The electronic, motorized ... for all applications of ... and hard specimens in ... labs. These instruments display ...
... Leica RM2255 rotary microtome, designed for ... and resin-embedded specimens, offers a broad ... research histology laboratory. This microtome meets ... a compact, fully motorized/electronic microtome for ...
State-of-the-Art modular embedding station providing performance and ease of use to meet the needs of the most demanding user....
... system for specimen surface preparation is the ... attachment Leica SP2600. ,Ultramilling is often a ... microtomy in sample preparation. Especially with difficult ... located side by side in one specimen ...
Medicine Products: